Evidence map›Paper›PMID 39985746›Full record

ArticleOphthalmology and therapy2025

Early Effects of Perfluorohexyloctane Ophthalmic Solution on Patient-Reported Outcomes in Dry Eye Disease: A Prospective, Open-Label, Multicenter Study.

Jason Bacharach, Shane R Kannarr, Anthony Verachtert, Preeya K Gupta, Moataz Razeen, Megan E Cavet, Jason L Vittitow, Jacob Lang, Thomas M Chester, Jillian F Ziemanski and 1 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06309953 phase4completednot on this map

An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

TypeinterventionalSponsorBausch & Lomb IncorporatedRan2024 to 2024Enrolled99ConditionsDry EyeArmsMiebo
NCT07268599 enrolling by invitationnot on this map

Acoltremon Symptom Tracking and Relief Assessment in Moderate-to-Severe Dry Eye Disease

TypeobservationalSponsorColvard Kandavel Eye CenterRan2025 to 2026Enrolled50ConditionsDry Eye Disease (DED)ArmsAcoltremon
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jason BacharachNorth Bay Eye Associates, Inc., 104 Lynch Creek Way, Suite 15, Petaluma, CA, 94954, USA. jbacharach@northbayeye.com.
Shane R KannarrKannarr Eye Care, Pittsburg, KS, USA.
Anthony VerachtertMoyes Eye Center, Kansas City, MO, USA.
Preeya K GuptaTriangle Eye Consultants, Raleigh, NC, USA.
Moataz RazeenBausch + Lomb, Bridgewater, NJ, USA.
Megan E CavetBausch + Lomb, Bridgewater, NJ, USA.
Jason L VittitowBausch + Lomb, Bridgewater, NJ, USA.
Jacob LangAssociated Eye Care, Hudson, WI, USA.
Thomas M ChesterCleveland Eye Clinic, Brecksville, OH, USA.
Jillian F ZiemanskiDepartment of Optometry and Vision Science, University of Alabama at Birmingham, Birmingham, AL, USA.
Darrell E WhiteSkyvision Centers, Westlake, OH, USA.

Funding

Bausch + Lomb, Bridgewater, NJ, USA Funding for editorial/writing assistanceBausch + Lomb, Rochester, NY, USA Rapid Service FeeBausch + Lomb, Rochester, NY, USA study funding
6 · The paper itself

Abstract

introductionPerfluorohexyloctane ophthalmic solution (PFHO) is indicated for the treatment of signs and symptoms of dry eye disease (DED) and targets excessive tear evaporation. This study evaluated patient-reported outcomes early in treatment with PFHO.

methodsThis prospective, multicenter, open-label, phase 4 study enrolled adults with a history of DED for ≥ 6 months. PFHO was instilled in both eyes four times daily for 14 days. Patients completed early outcome surveys during four clinic visits (day 1 [pretreatment; 5 and 60 min post-PFHO instillation] and days 3, 7, and 14). Symptom severity, symptom frequency, and treatment satisfaction were rated on visual analog scales (range 0-100). The primary endpoint was mean change from baseline in overall DED symptom severity at day 7. Secondary endpoints included change in severity of individual DED symptoms (eye dryness, blurred vision, eye irritation, light sensitivity, eye tiredness, burning/stinging, eye itching, eye pain); change in frequency (measured as percentage of time experienced) of the most bothersome symptom, awareness of dry eye symptoms, and fluctuation in quality of vision; and treatment satisfaction.

resultsNinety-nine patients enrolled (85.9% female; age range 35-81 years). The primary endpoint was met: mean (SD) overall symptom severity decreased significantly from 72.1 (17.0) at baseline to 27.8 (22.3) at day 7 (mean change, - 44.5; P < 0.0001). Mean (SD) percentage of time experiencing the most bothersome symptom decreased from 77.9% at baseline to 34.7% at day 14 (P < 0.0001). Significant reductions in severity and frequency also were observed for all symptoms at all postbaseline assessments (P < 0.0001). Median ratings of treatment satisfaction were 83.0 at day 3, 86.0 at day 7, and 90.0 at day 14.

conclusionEarly in the course of treatment with PFHO, patients with DED experienced significant reductions in dry eye symptom frequency and severity. Treatment satisfaction with PFHO was high.

trial registrationClinicalTrials.gov identifier NCT06309953.

Indexed as

Dry eyePatient-reported outcomesPerfluorohexyloctaneSymptoms

Identifiers

PMID39985746
PMCPMC11920460

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.